300831-46-3

Upstream product

• 85866-02-0 7-octene-1,2-diol 
• 300831-21-4 (S)-2-(tert-butoxycarbonylamino)non-8-enoic acid 
• 756894-33-4 ethyl (Z)-2-acetamido-2,8-nonadienoate 
• 300831-20-3 ethyl (S)-2-acetamido-8-nonenoate 
• 681260-04-8 (1R,2S)-1-amino-2-vinyl-cyclopropyl carboxylic acid methyl ester 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 17206-61-0 hept-6-enal 
• 300831-45-2 (1R,2S)-1-{[(2S,4S)-1-((S)-2-tert-Butoxycarbonylamino-non-8-enoyl)-4-hydroxy-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid methyl ester 
• 872496-94-1 (2S,4R)-2-((1R,2S)-1-Methoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(4-nitro-benzoyloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1565781-57-8 methyl (1R,2S)-1-{[(4S)-4-hydroxy-L-prolyl]amino}-2-vinylcyclopropanecarboxylate hydrochloride 
• 572922-89-5 (2S,4R)-4-hydroxy-2-[(1R,2S)-1-methoxycarbonyl-2-vinylcyclopropylcarbamoyl]pyrrolidine-1-carboxylic acid tert-butyl ester 
• 572922-91-9 (2S,4S)-4-Hydroxy-2-((1R,2S)-1-methoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 300832-84-2 ciluprevir 

Relevant academic research and scientific papers

Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans

(Equation Presented) The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigra

INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (I), (II) or (IV), or pharmaceutically acceptable salts and solvates thereof, which are useful as inhibitors of the Hepatitis C virus (HCV) protease enzyme and are also useful for the treatment of HCV infections in HCV--infected mammals, including humans. The present invention also provides pharmaceutical compositions comprising compounds of formula (I), (II) or (IV), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formulas (I), (II) and (IV).

Macrocyclic peptides active against the hepatitis C virus

Compounds of formula I: wherein R1 is hydroxy or NHSO2R1A wherein R1A is (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C1-6)alkyl, amido, amino or phenyl, or R1A is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O(C1-6)alkyl, amido, amino or phenyl; R2 is (C5-6)cycloalkyl and R3 is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.